| Recent progress in nanomaterials for gene delivery applications E Keles, Y Song, D Du, WJ Dong, Y Lin Biomaterials science 4 (9), 1291-1309, 2016 | 213 | 2016 |
| (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable … D Rageot, T Bohnacker, E Keles, JA McPhail, RM Hoffmann, A Melone, ... Journal of medicinal chemistry 62 (13), 6241-6261, 2019 | 56 | 2019 |
| Tumor resection recruits effector T cells and boosts therapeutic efficacy of encapsulated stem cells expressing IFNβ in glioblastomas SH Choi, DW Stuckey, S Pignatta, C Reinshagen, JK Khalsa, ... Clinical Cancer Research 23 (22), 7047-7058, 2017 | 49 | 2017 |
| Covalent proximity scanning of a distal cysteine to target PI3Kα C Borsari, E Keles, JA McPhail, A Schaefer, R Sriramaratnam, W Goch, ... Journal of the American Chemical Society 144 (14), 6326-6342, 2022 | 47 | 2022 |
| Preclinical development of PQR514, a highly potent PI3K inhibitor bearing a difluoromethyl–pyrimidine moiety C Borsari, D Rageot, F Beaufils, T Bohnacker, E Keles, I Buslov, A Melone, ... ACS medicinal chemistry letters 10 (10), 1473-1479, 2019 | 35 | 2019 |
| 4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and … C Borsari, E Keles, D Rageot, A Treyer, T Bohnacker, L Bissegger, ... Journal of medicinal chemistry 63 (22), 13595-13617, 2020 | 20 | 2020 |
| Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability C Borsari, E Keles, A Treyer, M De Pascale, P Hebeisen, M Hamburger, ... RSC medicinal chemistry 12 (4), 579-583, 2021 | 7 | 2021 |
| Tumor resection boosts therapeutic efficacy of encapsulated stem cells expressing a highly secretable variant of interferon-β in glioblastomas SH Choi, DW Stuckey, S Pignatta, C Reinshagen, JK Khalsa, ... Clin. Cancer Res 23 (22), 7047-7058, 2017 | 7 | 2017 |
| A novel, highly potent PI3Kα covalent inhibitor deconvolutes class I PI3K isoforms in cancer cells E Keles, C Borsari, R Sriramaratnam, T Schäfer, MP Wymann Cancer Research 81 (13_Supplement), 1378-1378, 2021 | 1 | 2021 |
| Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling L Bissegger, TA Constantin, E Keles, L Raguž, I Barlow-Busch, ... Chemical Science 15 (48), 20274-20291, 2024 | | 2024 |
| Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitors suitable for the treatment of CNS disorders C Borsari, E Keles, A Treyer, M De Pascale, P Hebeisen, M Hamburger, ... Cancer Research 81 (13_Supplement), 293-293, 2021 | | 2021 |
| Development of optimized chemical probes targeting PI3Ka to deconvolute the role of class I PI3Ks isoforms in insulin signaling M De Pascale, C Borsari, E Keles, J McPhail, A Schäfer, R Sriramaratnam, ... Cancer Research 81 (13_Supplement), 291-291, 2021 | | 2021 |
| Volume scanning, a rational approach to covalent PI3Kα inhibitors C Borsari, E Keles, J McPhail, A Schäfer, R Sriramaratnam, M De Pascale, ... Cancer Research 81 (13_Supplement), 1377-1377, 2021 | | 2021 |
| Novel PI3K and mTOR selective inhibitors to deconvolute PI3K signaling E Keles University_of_Basel, 2021 | | 2021 |
| Discovery and preclinical characterization of PQR626: A potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of tuberous sclerosis complex C Borsari, E Keles, D Rageot, A Melone, T Bohnacker, LK Batchelor, ... Cancer Research 80 (16_Supplement), 665-665, 2020 | | 2020 |
| Biomaterials Science LR Stevens, KJ Gilmore, GG Wallace, E Keles, Y Song, D Du, WJ Dong, ... | | |
